Back to top
more

Amgen (AMGN)

(Delayed Data from NSDQ)

$319.66 USD

319.66
1,467,828

+2.18 (0.69%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $319.25 -0.41 (-0.13%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Amgen (AMGN) Beats Q2 Earnings Estimates, to Buy Chemocentryx

Amgen (AMGN) beats Q2 estimates for earnings and sales. It offers to buy ChemoCentryx (CCXI) for $3.7 billion.

Amgen (AMGN) Q2 Earnings and Revenues Beat Estimates

Amgen (AMGN) delivered earnings and revenue surprises of 5.68% and 0.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Drug, Biotech Stocks' Q2 Earnings on Aug 4: LLY, AMGN & More

Let us look at four large drug and biotech companies, AMGN, VRTX, LLY, NVO, which are gearing up for their earnings release.

Analysts Estimate Heska (HSKA) to Report a Decline in Earnings: What to Look Out for

Heska (HSKA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amgen (AMGN) to Report Q2 Earnings: What's in the Cards?

Volume growth from Amgen's (AMGN) key drugs like Prolia, Xgeva, Repatha, and others is expected to have been partially offset by biosimilar/generic competition for mature drugs.

AbbVie's (ABBV) Q2 Earnings Beat Estimates, Revenues Lag

AbbVie's earnings (ABBV) beat estimates for second-quarter 2022, while sales miss the same. ABBV's immunology and neuroscience drugs drive sales. Shares decline in pre-market trading.

Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Amgen (AMGN) closed at $249.75, marking a -0.78% move from the previous day.

Pfizer (PFE) Q2 Earnings Top, COVID Products Drive Sales

Pfizer (PFE) beats estimates for Q2 earnings and sales. It maintains the sales forecast for COVID products, Comirnaty and Paxlovid.

Amgen (AMGN) Reports Next Week: Wall Street Expects Earnings Growth

Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Neena Mishra headshot

Should You Buy Beaten-Down Biotech Stocks & ETFs?

We highlight 4 ETFs that have started rebounding after a brutal sell-off

Amgen (AMGN) Gains As Market Dips: What You Should Know

Amgen (AMGN) closed at $245.95 in the latest trading session, marking a +0.07% move from the prior day.

Sweta Killa headshot

Healthcare ETFs in Focus Ahead of Q2 Earnings

The healthcare sector has gained some momentum lately on investors' rush to safety in a volatile stock market. The sector is non-cyclical in nature, which in turn, is providing a cushion to the portfolio.

Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know

Amgen (AMGN) closed the most recent trading day at $246.63, moving -0.28% from the previous trading session.

Is Trending Stock Amgen Inc. (AMGN) a Buy Now?

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Should You Invest in the VanEck Biotech ETF (BBH)?

Sector ETF report for BBH

The Zacks Analyst Blog Highlights Eli Lilly, Thermo Fisher Scientific, TotalEnergies, Amgen and Marathon Petroleum

Eli Lilly, Thermo Fisher Scientific, TotalEnergies, Amgen and Marathon Petroleum have been included in this Analyst Blog.

Sheraz Mian headshot

Top Stock Reports for Eli Lilly, Thermo Fisher & TotalEnergies

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Thermo Fisher Scientific Inc. (TMO), and TotalEnergies SE (TTE).

Why Amgen (AMGN) Could Beat Earnings Estimates Again

Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Amgen (AMGN) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Amgen (AMGN) closed at $245.59, marking a -0.61% move from the previous day.

Amgen (AMGN) Gains As Market Dips: What You Should Know

In the latest trading session, Amgen (AMGN) closed at $247.09, marking a +0.05% move from the previous day.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

Smart Beta ETF report for IBB

Radius (RDUS) Randomizes Patient in Prader-Willi Syndrome Study

Radius (RDUS) randomizes the first patient in the SCOUT-015 study of pipeline candidate, RAD011, for Prader-Willi Syndrome.

Amgen (AMGN) Gains But Lags Market: What You Should Know

In the latest trading session, Amgen (AMGN) closed at $247.42, marking a +0.88% move from the previous day.

Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?

Style Box ETF report for SCHD